Pfizer 2Q Revenues: $19.0 billion (+92%) 2Q Earnings: $5.6 billion (+59%) Comments: Vaccines sales were $9.2 billion in the quarter, up from $1.2 billion in 2Q20. COVID-19 vaccine BNT162b2 contributed $7.8 billion in sales and alliance revenues. Prevnar 13 sales were up 11% to $1.3 billion. Oncology sales were $3.1 billion, up 19%. Ibrance sales were $1.4 billion, up 4%. Inlyta sales were up 32% to $257 million. Xtandi alliance revenues were $303 million, up 14%. Internal Medicine sales were ...